Lindsay M. Burke defends and asserts the rights of companies entangled in complex disputes. Her cases often involve non-competition agreements, trade secret litigation, questions regarding intellectual property ownership, business-to-business contract disputes, and business divorce. Lindsay has significant experience representing clients before the Business Litigation Session of the Massachusetts Superior Court, the United States District Court for the District of Massachusetts, and state and federal courts in New York. Lindsay is recognized as one of the “Top Women of Law” and an “Up and Coming Lawyer” by Massachusetts Lawyer’s Weekly and a Rising Star/SuperLawyer by Super Lawyers. She is a Trustee of the Women’s Bar Foundation and co-chair of the Women’s Bar Association’s Women in the Courtroom Committee. Before joining Kenney & Sams, Lindsay worked at WilmerHale in Boston and Sullivan & Cromwell in New York City. She received her undergraduate degree from the College of William & Mary in Williamsburg, Virginia, and her J.D. from New York University School of Law.

Dr. Fehlner leads Axcella’s Intellectual Property and product exclusivity strategy. Prior to assuming this role, Dr. Fehlner was a Principal of Life Sciences Innovation LLC, a consulting company he founded in 2017 to advise on complex IP business strategy for products and technologies in life sciences, develop capabilities of legal and IP professionals, and provide BD&L support for research institutes, companies, and investors. He has been named to the IAM Strategy 300 World’s Leading Patent Professionals for the past four years. Previously, Dr. Fehlner spent nine years as the Head of Intellectual Property for Novartis Pharma in Basel, Switzerland. In this role, he led a team responsible for obtaining, maintaining, and enforcing IP rights. The team created holistic portfolios of patents, trademarks, regulatory exclusivities, and reputation for Novartis products. Dr. Fehlner joined Novartis in 2008 from Baker Botts, where he was a partner specializing in IP counselling and strategic planning in the pharmaceutical, biotechnology and medical device industries, as well as litigation. Prior to that he was an associate and partner at Darby & Darby, with earlier experience as Biotechnology Counsel for Rhône-Poulenc Rorer and as an associate for boutique IP firm Klauber & Jackson. Dr. Fehlner started his career in 1990 as a law clerk in the biotech and pharmaceutical group at Pennie & Edmonds. In addition to life sciences, Dr. Fehlner has worked on chemical and material sciences technologies. Dr. Fehlner has a JD from Fordham University School of Law, a PhD in immunology and biochemistry from Rockefeller University (Lois P Markey Fellow), and a BS in chemistry from Haverford College (high honors; Phi Beta Kappa).

Robert Haney is a partner in the New York office with 30 years of experience litigating complex commercial disputes including conducting arbitrations, jury trials, bench trials, and mediations for major corporations as well as small and mid-sized biotech, financial, and technology firms. He has participated and advised with respect to employment law issues in numerous internal investigations including recent high profile investigations where he advised on employment contract issues involving CEO’s and other senior executives. While experienced in the full range of business and financial disputes, Mr. Haney has particular proficiency conducting arbitrations and trials involving the departure of senior executives and partners, trade secrets and securities and consumer class actions.

Michelle represents clients in all phases of litigation, from pre-suit investigation to pleadings, discovery, motion practice, trials, and appeals. She has experience working with pharmaceutical and biotechnology companies, medical device manufacturers, financial technology companies, universities, and car and personal watercraft manufacturers on a broad range of complex litigation matters. Michelle received her J.D. from Northwestern University Pritzker School of Law and her undergraduate degree in Public Policy from the University of Michigan.

Dan Shores is a Partner at Rothwell Figg and a founder of its Boston office. He has an extensive background in IP law in the biotech space and has been practicing in that space during the entirely of his 17-year career including in matters relating to small molecules, biosimilars, mRNA, LNP, and oligonucleotide technologies. Dan is passionate about helping his clients build robust patent portfolios, litigate matters (both as plaintiffs and defendants in the U.S. District Courts and in IPR and other post-grant proceedings), protect trade secrets, negotiate strategic collaborations, conduct due diligence and landscape investigations, and prepare for success in funding rounds and exits. Dan is a problem-solver who excels at deciphering key translational aspects of a broad array of technologies to maximize leverage in the context of clients’ desired implementation of such technologies whether as participants in dynamic markets or as first movers. Dan is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts. Dan lives in Boston with his wife Lindsay, their daughter Audrey, and their two English Bulldogs Jarves and Rosie.